Navigation Links
CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcare's Centricity(R) Electronic Medical Record (EMR) System
Date:8/5/2008

GE Centricity(R) -- Third Largest U.S. Outpatient EMR with Nearly 10%

Market Share

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company's BioZ(R) Dx now seamlessly integrates with General Electric Healthcare's Centricity(R) electronic medical record (EMR) system.

The Company released this week its latest version of BioZport(R) ICG data management software which includes capabilities to automatically integrate and transfer BioZ(R) ICG data from the BioZ(R) Dx to GE Healthcare's Centricity(R) EMR system. This is a strategic advancement for the Company's flagship product as EMR interface and paperless workflow are increasingly becoming necessities to the outpatient physician when making decisions on new medical technologies. Currently, it is estimated that 24% of U.S. outpatient physicians utilize an EMR system. Medical device to EMR interface capability will continue to grow in importance as U.S. outpatient-based physician use of EMR is forecasted to grow at over 16% per year through 2013.

Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We are extremely pleased to release our initial BioZ ICG direct EMR interface. EMR is a driving, essential factor in the majority of medical device decisions for early adopter physicians and large physician practices. Interfacing with our long-time partner, GE Healthcare, whose Centricity(R) system has nearly 10% share in our sizable outpatient physician market, is a great accomplishment for our company, customers, prospective customers and investors."

Perry continued, "Our EMR strategy is to partner with the top 10% to 15% of EMR suppliers, who collectively have 80% of U.S. outpatient market share. Allscripts, the second largest outpatient EMR provider, with over 12% market share, is our next planned interface. With inc
'/>"/>

SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
2. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
3. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
4. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
5. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
6. CardioDynamics Provides 2007 Shareholder Meeting Update
7. New Book on the Business of Biotechnology
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. eResearchTechnology Reports Second Quarter 2008 Results
10. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
11. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 According to ... Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web ... Forecasts & Trends to 2018", published by MarketsandMarkets, analyzes ... geographies such as North America , ... , and the Rest of the World (RoW). ...
(Date:7/29/2014)... , July 29, 2014  Discovery Laboratories, ... to advancing a new standard of respiratory critical ... on August 5, 2014 before the open of ... Company will host a live teleconference and webcast ... the conference call, Discovery Labs, management will discuss ...
(Date:7/29/2014)... Calif. , July 29, 2014 /PRNewswire-iReach/ -- ... agreement with FORMA Therapeutics, Inc., to provide access ... proprietary fragment-based lead discovery platform for novel small ... excited about the opportunity to work with FORMA ... of epigenetics and protein homeostasis. FORMA Therapeutics, decision ...
(Date:7/29/2014)... , July 29, 2014 ... surgical equipment market (types, applications and geography) - Size, ... Report, Opportunities, Segmentation and Forecast, 2013 - 2020", suggests ... reach $12.1 billion by 2020 registering a CAGR of ... the breakthrough achieved by the electro surgical devices in ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3
... 3 .decimal, Inc. announced today that,it has ... to supply,patient-specific devices for its proton therapy facility ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/CLTU104LOGO ) , ... a formal agreement signed with ProCure to be,their ...
... Sleep Apnea TreatmentSAN CARLOS, Calif., Feb. 3 ... shown their patients comply with Obstructive Sleep Apnea ... average.Analysis performed in October 2008 looked at Northern ... treatment with Positive Airway Pressure beginning in early ...
... Feb. 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... Surveillance Agency, has granted BioMarin marketing approval for Naglazyme(R) ... (MPS VI)."We are very pleased to receive marketing approval ... number of affected MPS VI patients in the world," ...
Cached Biology Technology:ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City 2SleepQuest Compliance Again Doubles Industry Average 2Naglazyme Approved by Brazil's National Health Surveillance Agency 2Naglazyme Approved by Brazil's National Health Surveillance Agency 3Naglazyme Approved by Brazil's National Health Surveillance Agency 4
(Date:7/29/2014)... ordered the wrong food at a restaurant, don,t blame yourself; ... to do with what you want and more to do ... menus and the selections of over 300 diners, the Cornell ... Hospitality Management showed that when it comes to what ... see on the menu and how you imagine it will ...
(Date:7/29/2014)... , July 29, 2014 Research ... "Global SaaS-based Business Intelligence (BI) Market 2014-2018" report ... The term BI refers to ... access to, or analyzing information about a company,s operations. ... factors affecting their business; for example, metrics on sales, ...
(Date:7/29/2014)... locomotion. Swimming microorganisms, such as bacteria and spermatozoa, are ... viscous forces exerted by the surrounding fluid. Such ... have found that the direction of propulsion made possible ... a viscoelastic fluid. These findings have been published in ... Alternative Energies and Atomic Energy Commission (CEA), in Le ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Optimum inertial self-propulsion design for snowman-like nanorobot 2
... cartilage injuries can be effectively repaired by tissue ... process concludes research led by scientists at the ... tissue engineered cartilage implanted in injured and osteoarthritic ... 12, Number 7) issue of Tissue Engineering, demonstrates ...
... that helps them recognize and isolate foreign DNA trying ... of Washington-led study in the June 8 issue of ... the Sidney Kimmel Cancer Center in San Diego, could ... bacteria. The findings may also impact the biotech industry, ...
... who are extremely obese may be underestimated as a new ... and high cholesterol than women at lower levels of obesity, ... JAMA. , Obesity diagnosis and treatment are typically based on ... calculated as weight in kilograms divided by height in meters ...
Cached Biology News:Bacteria have their own immune system protecting against outside DNA 2Higher levels of obesity associated with greater health risks 2Higher levels of obesity associated with greater health risks 3
Request Info...
Request Info...
XBP-1 (F-4)...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Biology Products: